Latest news with #RxSight®LightAdjustableLens
Yahoo
5 days ago
- Business
- Yahoo
RxSight, Inc. to Report Second Quarter 2025 Financial Results on August 7, 2025
ALISO VIEJO, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the second quarter of 2025 after the market close on Thursday, August 7, 2025. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 633359. The call will also be broadcast live in listen-only mode via a link on the company's investor relations website at An archived recording of the call will be available through the same link shortly after its completion. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, collectively the 'LAL'), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at Company Contact:Shelley B. ThunenChief Financial Officersthunen@ Investor Relations Contact:Oliver MoravcevicVP, Investor Relationsomoravcevic@
Yahoo
23-04-2025
- Business
- Yahoo
RxSight, Inc. to Report First Quarter 2025 Financial Results on May 7, 2025
ALISO VIEJO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the first quarter of 2025 after the market close on Wednesday, May 7, 2025. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 8740296. The call will also be broadcast live in listen-only mode via a link on the company's investor relations website at An archived recording of the call will be available through the same link shortly after its completion. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®, collectively the 'LAL'), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at Company Contact:Shelley B. ThunenChief Financial Officersthunen@ Investor Relations Contact:Oliver MoravcevicVP, Investor Relationsomoravcevic@ in to access your portfolio
Yahoo
25-03-2025
- Business
- Yahoo
RxSight, Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference
ALISO VIEJO, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming 24th Annual Needham Virtual Healthcare Conference. RxSight's management is scheduled to participate in a fireside chat on Tuesday, April 8, 2025, at 9:45 a.m. Pacific Time / 12:45 p.m. Eastern Time. A live and archived webcast of the presentation will be available on the Company's investor relations website at About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL™/LAL+®, collectively the 'LAL'), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at Company Contact:Shelley B. ThunenChief Financial Officersthunen@ Investor Relations Contact:Oliver MoravcevicVP, Investor Relationsomoravcevic@ in to access your portfolio
Yahoo
11-02-2025
- Business
- Yahoo
RxSight, Inc. to Report Fourth Quarter Financial Results on February 25, 2025
ALISO VIEJO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that it will report financial results for the fourth quarter of 2024 after the market close on Tuesday, February 25, 2025. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 7159871. The call will also be broadcast live in listen-only mode via a link on the company's investor relations website at An archived recording of the call will be available through the same link shortly after its completion. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL™/LAL+®, collectively the 'LAL'), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at Company Contact:Shelley B. ThunenChief Financial Officersthunen@ Investor Relations Contact:Oliver MoravcevicVP, Investor Relationsomoravcevic@ in to access your portfolio
